BR112019001178A2 - biotinas e composição de biotina - Google Patents

biotinas e composição de biotina

Info

Publication number
BR112019001178A2
BR112019001178A2 BR112019001178-1A BR112019001178A BR112019001178A2 BR 112019001178 A2 BR112019001178 A2 BR 112019001178A2 BR 112019001178 A BR112019001178 A BR 112019001178A BR 112019001178 A2 BR112019001178 A2 BR 112019001178A2
Authority
BR
Brazil
Prior art keywords
biotins
biotin
biotin composition
composition
relates
Prior art date
Application number
BR112019001178-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Sedel Frédéric
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of BR112019001178A2 publication Critical patent/BR112019001178A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112019001178-1A 2016-07-29 2017-07-28 biotinas e composição de biotina BR112019001178A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
EP16305989.2 2016-07-29
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
BR112019001178A2 true BR112019001178A2 (pt) 2019-04-30

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001178-1A BR112019001178A2 (pt) 2016-07-29 2017-07-28 biotinas e composição de biotina

Country Status (24)

Country Link
US (2) US10117854B2 (https=)
EP (2) EP3275439A1 (https=)
JP (1) JP2019522030A (https=)
KR (1) KR20190034550A (https=)
AU (1) AU2017303346A1 (https=)
BR (1) BR112019001178A2 (https=)
CA (1) CA3031302A1 (https=)
CY (1) CY1122348T1 (https=)
DK (1) DK3319601T3 (https=)
EA (1) EA201990413A1 (https=)
ES (1) ES2751154T3 (https=)
HK (1) HK1254833B (https=)
HR (1) HRP20191798T1 (https=)
HU (1) HUE046590T2 (https=)
IL (1) IL264460B (https=)
LT (1) LT3319601T (https=)
MA (1) MA42419B1 (https=)
ME (1) ME03520B (https=)
PL (1) PL3319601T3 (https=)
PT (1) PT3319601T (https=)
RS (1) RS59300B1 (https=)
SI (1) SI3319601T1 (https=)
SM (1) SMT201900628T1 (https=)
WO (1) WO2018020010A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
CN116173182A (zh) * 2023-03-31 2023-05-30 苏州融析生物科技有限公司 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
ES2751154T3 (es) 2020-03-30
CY1122348T1 (el) 2021-01-27
DK3319601T3 (da) 2019-11-18
HRP20191798T1 (hr) 2019-12-27
SMT201900628T1 (it) 2020-01-14
US10328059B2 (en) 2019-06-25
ME03520B (me) 2020-04-20
CA3031302A1 (en) 2018-02-01
EP3275439A1 (en) 2018-01-31
IL264460B (en) 2021-06-30
AU2017303346A1 (en) 2019-01-31
KR20190034550A (ko) 2019-04-02
EP3319601B1 (en) 2019-08-28
HK1254833B (en) 2020-05-22
EA201990413A1 (ru) 2019-06-28
PL3319601T3 (pl) 2020-06-29
LT3319601T (lt) 2019-11-11
PT3319601T (pt) 2019-09-18
WO2018020010A1 (en) 2018-02-01
JP2019522030A (ja) 2019-08-08
US10117854B2 (en) 2018-11-06
US20190070150A1 (en) 2019-03-07
MA42419B1 (fr) 2019-11-29
EP3319601A1 (en) 2018-05-16
HUE046590T2 (hu) 2020-03-30
SI3319601T1 (sl) 2019-11-29
RS59300B1 (sr) 2019-10-31
IL264460A (en) 2019-02-28
US20180214417A1 (en) 2018-08-02
MA42419A (fr) 2018-05-16

Similar Documents

Publication Publication Date Title
MX2022007607A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
CL2018000070A1 (es) Modulares de diaciglicerol aciltransderasa 2 (dgta2)
CL2015002677A1 (es) Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o condiciones asociadas con la disfunción mitocondrial.
BR112017017217A2 (pt) ?composição que compreende ramnolipídeo e siloxano?
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
CO2020008769A2 (es) Moduladores de la expresión dnm2
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
MX2018010683A (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
BR112019001178A2 (pt) biotinas e composição de biotina
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
BR112016008901A2 (pt) Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor.
CL2021000660A1 (es) Compuestos quelantes de hierro para tratar condiciones estéticas de la piel
BR112017018618A2 (pt) odorizante de osmanthus
MX386393B (es) Andrografólido para tratar formas progresivas de esclerosis múltiple.
CO2020003134A2 (es) Moduladores de la expresión de enac
MX2017011904A (es) Composiciones para el tratamiento de fibrosis y afecciones relacionadas con fibrosis.
MX2017004909A (es) Composiciones de triptamina y metodos de uso.
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.